1. Vitamin D and new-onset atrial fibrillation: A meta-analysis of randomized controlled trials.
- Author
-
Huang WL, Yang J, Yang J, Wang HB, Yang CJ, and Yang Y
- Subjects
- Humans, Vitamins pharmacokinetics, Atrial Fibrillation blood, Atrial Fibrillation physiopathology, Atrial Fibrillation prevention & control, Randomized Controlled Trials as Topic, Stroke Volume drug effects, Ventricular Function, Left drug effects, Vitamin D pharmacokinetics
- Abstract
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, which affects 1.5% to 2% of the general population. More than six million Europeans suffer from AF. To research vitamin D levels in the prevention of new-onset atrial fibrillation (AF), we conducted a systematic review of randomized controlled trials (RCTs). We focused on the vitamin D levels in the prevention of new-onset AF. The outcomes assessed were vitamin D levels, left ventricular ejection fraction (LVEF), and left atrium diameter. Six RCTs ultimately met the inclusion criteria in the meta-analysis. The outcomes of Vitamin D levels (MD = -4.27, 95% CI = -5.20 to-3.34, P = 0.30) in the new-onset AF showed no significant difference. The left atrium diameter (MD = 1.96, 95% CI = 1.48 to 2.60, P < 0.01) between new-onset AF and LVEF (MD = -0.92, 95% CI = -1.59 to -0.26, P < 0.01) showed significant difference. Our study shows that circulating vitamin D levels may not play a major role in the development of new-onset AF., (Copyright © 2017 Hellenic Society of Cardiology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF